Skip to main content
Full access
Communications and Updates
Published Online: 1 August 2011

Involuntary Movements Associated with Cetirizine Use

To the Editor: Cetirizine is approved by the U.S. Food and Drug Administration (FDA) for allergic rhinitis in all age groups (1). Published reports have described cetirizine-induced dystonic reactions in the pediatric patient population and in one adult (24). We present the case of an adult who developed involuntary movements associated with cetirizine use and discontinuation.

Case Report

A 24-year-old Caucasian woman presented to the local hospital emergency department with a nose laceration she sustained from walking into a glass window after acute alcohol intoxication (her blood alcohol level was 140 mg/dL). She reported taking 10 mg/day of cetirizine for 3 months, daily valacyclovir (for herpes simplex virus 1), and depot medroxyprogesterone. She denied a history of medication side effects, denied taking more than the recommended dosage, and was not taking over-the-counter or herbal products. She denied a history of head injuries, seizures, or loss of consciousness, and she also denied treatment with psychotropic medications. Initially, results from her physical examination were unremarkable with the exception of a superficial laceration on her nose. The results of laboratory testing, including thyroid-stimulating hormone and urine toxicology, were all within normal limits or negative.
While in the emergency department, the patient developed acute involuntary “bizarre grimacing” and dysarthria. There was no evidence of oculogyric crisis, torticollis, tongue protrusions, opisthotonos, gait disturbances, or weakness in her extremities. She did not lose consciousness, and results of her neurological examination were negative. She was given intravenous diphenhydramine (50 mg), benztropine (2 mg), and lorazepam (2 mg). Neuroimaging results of her head and spine were negative, and her dystonia had resolved by the time a neurologist arrived at her bedside.
A follow-up call 1 month later revealed that the patient had stopped taking cetirizine after she was discharged from the emergency department. She reported facial twitching on the day after discharge. Over the course of the month, she experienced two episodes of difficulty walking, hand “discoordination,” and “muscle jerks of her throat.” These episodes lasted approximately 20 minutes. An outpatient neurology consultation was arranged at the time of the call, but it is not known whether she kept that appointment.

Discussion

Cetirizine is a carboxylated metabolite of hydroxyzine (a piperazine histamine H1 receptor antagonist) (1). Piperazines have central dopamine D2 receptor blockade (5). Cetirizine's large size, lipophobic nature, and greater affinity for peripheral H1 receptors are believed to reduce CNS penetration and central side effects (2). However, one positron emission tomography study of cetirizine revealed approximately 30% H1 receptor binding in the cerebral cortex (1, 2). Cetirizine has negligible anticholinergic activity (6). We speculate that as a piperazine derivative, cetirizine blocked the striatal D2 receptors and resulted in an acute dystonic reaction in our patient. In addition, we also speculate that our patient's 3-month cetirizine use resulted in D2 receptor hypersensitivity similar to that observed in long-term antipsychotic use, with subsequent involuntary movements after its discontinuation. It is also possible that her cetirizine use and the subsequent development of involuntary movements are independent events. More research is needed to clarify cetirizine's effect on central D2 receptors.

Footnote

This letter was accepted for publication in May 2011.

References

1.
Curran MP, Scott LJ, Perry CM: Cetirizine: a review of its use in allergic disorders. Drugs 2004; 64:523–561
2.
Rajput A, Baerg K: Cetirizine-induced dystonic movements. Neurology 2006; 66:143–144
3.
Esen I, Demirpence S, Yis U, Kurul S: Cetirizine-induced dystonic reaction in a 6-year-old boy. Pediatr Emerg Care 2008; 24:627–628
4.
Fraunfelder FW, Fraunfelder FT: Oculogyric crisis in patients taking cetirizine. Am J Ophthalmol 2004; 134:355–357
5.
Sadock BJ, Sadock VA: Kaplan and Sadock's Synopsis of Psychiatry, 10th ed. Edited by, Grebb JA, Pataki CS, Sussman N. Philadelphia, Lippincott Williams & Wilkins, 2007, pp 1043–1056
6.
Zyrtec (cetirizine hydrochloride) package insert. http://daily-med.nlm.nih.gov/dailymed/drugInfo.cfm?id=2115

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 855
PubMed: 21813500

History

Accepted: May 2011
Published online: 1 August 2011
Published in print: August 2011

Authors

Details

Candace A. Romo, M.D.
Kaustubh G. Joshi, M.D.
Brian M. Waters, M.D.

Funding Information

The authors report no financial relationships with commercial interests. The opinions expressed in this letter do not reflect those of the Department of Defense or the United States Air Force.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share